Spots Global Cancer Trial Database for Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
Official Title: An Open Label Multi-Center Phase II Study of RAD001 in Advanced Thyroid Cancer
Study ID: NCT01164176
Conditions
Study Description
Brief Summary: RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well everolimus works in treating patients with locally advanced or metastatic thyroid cancer.
Detailed Description: OBJECTIVES: Primary * To evaluate response rate in patients with locally advanced or metastatic, unresectable or refractory thyroid cancer treated with everolimus. Secondary * To evaluate overall survival of these patients treated with everolimus. * To evaluate progression-free survival of these patients. * To evaluate toxicity of this therapy in these patients. OUTLINE: This is a multicenter study. Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected periodically for correlative studies. After completion of study treatment, patients are followed up for 12 months.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, , Korea, Republic of
Yeungnam University Medical Center, Daegu, , Korea, Republic of
National Cancer Center - Korea, Goyang, , Korea, Republic of
Kosin Medical Center Gospel Hospital, Pusan, , Korea, Republic of
Seoul National University Hospital, Seoul, , Korea, Republic of
Yonsei Cancer Center at Yonsei University Medical Center, Seoul, , Korea, Republic of
Gangnam Severance Hospital, Seoul, , Korea, Republic of
Contact Details
Name: Byung Chul Cho
Affiliation: Yonsei University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
